Anti-IL-5 Antibody Formulation Stability Against Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compositions for treating IL-5 mediated diseases, such as asthma and eosinophilic disorders, do not effectively maintain the biological function of mepolizumab due to issues like deamidation, oxidation, and aggregation, which affect the antibody's efficacy.
Innovation Solution
A composition comprising anti-IL-5 antibodies with specific heavy and light chain sequences (SEQ ID NO: 1 and 2) and controlled levels of deamidated and oxidized variants, formulated in an aqueous solution with specific pH and additives to stabilize the antibody.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mepolizumab is used to treat IL-5 mediated diseases, then therapeutic efficacy is improved, but biological function is compromised due to deamidation, oxidation, and aggregation
Solution Approach 1:
The patent applies parameter changes by precisely controlling the chemical environment (pH 6.3, ionic strength, temperature) and formulation conditions to minimize deamidation, oxidation, and aggregation. The composition specifies exact concentrations of stabilizing agents (sucrose 12%, polysorbate 80 0.02%, EDTA 0.05 mM) and buffer components to maintain antibody structural integrity and prevent degradation pathways while preserving therapeutic activity.
Solution Approach 2:
The patent introduces intermediary substances (stabilizing agents, buffers, excipients) that mediate between the antibody and its environment. These intermediaries include sucrose as a cryoprotectant, polysorbate 80 as an anti-aggregation agent, EDTA as a chelating agent, and phosphate/citrate buffers to maintain pH, thereby protecting the antibody from direct exposure to harmful conditions.
2Ease of manufacture
If deamidation and oxidation occur in the antibody, then manufacturing simplicity is maintained, but therapeutic efficacy is reduced
Solution Approach 1:
The patent applies preliminary action by incorporating stabilizing agents and anti-degradation compounds into the formulation before administration. The composition is pre-formulated with specific concentrations of protective agents (polysorbate 80, EDTA, sucrose) that prevent deamidation and oxidation from occurring during storage and administration, thereby maintaining therapeutic efficacy without complicating the manufacturing process.
Solution Approach 2:
The patent controls formulation parameters (pH 6.3, ionic strength, temperature, concentration of stabilizing agents) to create an environment that inhibits degradation pathways. By optimizing these parameters, the formulation maintains antibody integrity and therapeutic efficacy while remaining relatively simple to manufacture using standard biopharmaceutical processes.
3Device complexity
If aggregation occurs in the antibody composition, then production complexity is reduced, but biological activity is compromised
Solution Approach 1:
The patent introduces intermediary substances (polysorbate 80 at 0.02%, EDTA at 0.05 mM, sucrose at 12%) that act as mediators to prevent aggregation. These agents interfere with intermolecular interactions that lead to aggregation, thereby maintaining antibody monomeric form and biological activity without significantly increasing formulation complexity.
Solution Approach 2:
The patent optimizes formulation parameters including ionic strength, pH (6.3), temperature, and concentration of protective agents to minimize aggregation tendencies. By controlling these parameters, the formulation maintains antibody solubility and prevents aggregation while remaining relatively simple to prepare using conventional biopharmaceutical manufacturing techniques.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.